Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 21   

Articles published

ANTH 1.86 -0.04 (-2.11%)
price chart
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH ...
Last Friday, Kevin Kotler's Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH). According to a Schedule 13G filed with the Securities and Exchange Commission, the fund now owns ...
Top News : International Business Machines Corporation (NYSE:IBM), Anthera ...
Anthera Pharmaceuticals Inc (NASDAQ:ANTH), whose shares are down more than 41% this year, said it was in talks that could lead to an important partnership arrangement regarding blisibimod, its product in the pipeline.
Anthera Pharmaceuticals Announces Update on Strategic Partnership ...
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Related articles »  
Anthera Pharmaceuticals Downgraded by Zacks to Neutral (ANTH)
Anthera Pharmaceuticals Inc logo Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a research report issued on Tuesday.
Related articles »  
Anthera Pharmaceuticals Stock Rating Lowered by Zacks (ANTH)
Anthera Pharmaceuticals Inc logo Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a research note issued to investors on Tuesday.
Related articles »  
News Buzz: Merck & Co. Inc. (NYSE:MRK), Staples, Inc. (NASDAQ:SPLS ...
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.15.
Stocks to Watch: The Manitowoc Company(NYSE:MTW), Microchip Technology ...
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) on 1st october confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Related articles »  
Eli Lilly stops development of lupus drug; XTL shares soar
(Reuters) - Eli Lilly and Co said it would stop the development of its drug to treat the autoimmune disorder lupus, after it was found to be not effective enough in late-stage trials.
Related articles »  
Stock Highlights: JPMorgan Chase & Co. (NYSE:JPM), iBio (NYSEMKT:IBIO ...
On 1 October Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Top Losers After-Hours NASDAQ � ANTH, PRAA, SPEX, KERX, DGLY, CSII, JDSU
Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) traded at $1.67 down -7.2 percent during After-Hours sessions on 34100 total share volume.